John Flavin is a notable entrepreneur and corporate executive with a distinguished track record in building innovative companies within the healthcare sector. Known for his leadership at several biotechnology firms, he has been instrumental in developing groundbreaking therapies that address critical medical needs. His extensive experience includes not only operational oversight but also strategic vision in navigating complex regulatory landscapes. He has served on various boards, contributing insights into market trends and business strategy while fostering partnerships aimed at driving growth. Through these roles, Flavin demonstrates profound relevance to investors focused on advancements in life sciences and health technology.
John Flavin is a notable entrepreneur and corporate executive with a distinguished track record in building innovative companies within the healthcare sector. Known for his leadership at several biotechnology firms, he has been instrumental in developing groundbreaking therapies that address critical medical needs. His extensive experience includes not only operational oversight but also strategic vision in navigating complex regulatory landscapes. He has served on various boards, contributing insights into market trends and business strategy while fostering partnerships aimed at driving growth. Through these roles, Flavin demonstrates profound relevance to investors focused on advancements in life sciences and health technology.
The healthcare sector presents transformative investment opportunities fueled by rapid technological advancements. John Flavin leverages his extensive entrepreneurial and operational background to identify high-potential ventures that aim to revolutionize patient care. By focusing on companies capable of delivering innovative solutions, he adopts a proactive approach in evaluating emerging markets and technologies. This strategic mindset allows him to capitalize on industry trends while forging valuable partnerships within the life sciences ecosystem. In fostering collaboration with key stakeholders, Flavin strives for impactful outcomes that align health innovation with sustainable business growth.
The healthcare sector presents transformative investment opportunities fueled by rapid technological advancements. John Flavin leverages his extensive entrepreneurial and operational background to identify high-potential ventures that aim to revolutionize patient care. By focusing on companies capable of delivering innovative solutions, he adopts a proactive approach in evaluating emerging markets and technologies. This strategic mindset allows him to capitalize on industry trends while forging valuable partnerships within the life sciences ecosystem. In fostering collaboration with key stakeholders, Flavin strives for impactful outcomes that align health innovation with sustainable business growth.
| Trades 1328 | Longs Won 985/1328 74% | Profit Factor 13.76 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $538,357.68 |
| Average Win $158,904.12 | Best Trade (Aug 14) $12.37M | Sharpe Ratio -13.11 |
| Average Loss -$33,172.75 | Worst Trade (Jun 30) -$1.09M | Z-Score 17.03 (100%) |
| Commissions $0 | Avg. Trade Length 1y 7m 3w 3d | Expectancy $109,293.9 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 15,873 | 14,286 | 12,698 | 11,111 | 9,524 | 7,937 | 6,349 | 4,762 | 3,175 | 1,587 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
AAPL Apple Inc. | 22,596 | $4.14M | $7.03M | - | $2.89M | 69.72% | +0.524% |
ABBV AbbVie Inc. | 1,227 | $286,115.09 | $299,142.6 | - | $13,027.51 | 4.55% | 0.0 |
AFRM Affirm Holdings, Inc. | 8,507 | $590,505.89 | $674,775.24 | - | $84,269.35 | 14.27% | +1.536% |
AGNG Global X Aging Population ETF | 67,440 | $2.4M | $2.51M | - | $106,130.95 | 4.42% | +0.189% |
AIQ Global X Artificial Intelligence & Technology ETF | 74,070 | $3.46M | $4.49M | - | $1.02M | 29.5% | -4.055% |
AKRE Akre Focus ETF | 43,964 | $2.88M | $2.53M | - | -$352,591.28 | -12.24% | -1.844% |
ALK Alaska Air Group Inc. | 9,397 | $380,688.14 | $490,711.34 | - | $110,023.2 | 28.9% | -0.628% |
AMD Advanced Micro Devices, Inc. | 1,051 | $170,041.29 | $545,027.6 | - | $374,986.31 | 220.53% | 0.0 |
AMGN Amgen Inc. | 1,500 | $367,508.52 | $585,029.98 | - | $217,521.46 | 59.19% | 0.0 |
AMZN Amazon.com Inc | 24,270 | $3.91M | $6.73M | - | $2.82M | 72.03% | 0.0 |
ARKQ Ark Autonomous Technology & Robotics ETF | 44,369 | $5.12M | $5.54M | - | $421,514.71 | 8.24% | 0.0 |
AVGO Broadcom Inc. | 537 | $202,851.75 | $224,551.92 | - | $21,700.17 | 10.7% | 0.0 |
AVUV Avantis U.S. Small Cap Value ETF | 45,096 | $4.35M | $5.81M | - | $1.45M | 33.42% | 0.0 |
BA Boeing Company | 6,490 | $1.28M | $1.54M | - | $260,812.91 | 20.4% | 0.0 |
BFOR Barron's 400 ETF | 26,588 | $595,252.14 | $645,290.76 | - | $50,038.62 | 8.41% | -0.736% |
BMY Bristol-Myers Squibb Company | 11,306 | $511,452.66 | $719,400.78 | - | $207,948.12 | 40.66% | -3.43% |
BND Vanguard Total Bond Market Index Fund | 261,716 | $18.93M | $18.9M | - | -$26,336.81 | -0.14% | -0.29% |
BRK-B Berkshire Hathaway Inc. | 4,881 | $1.72M | $2.52M | - | $800,021.9 | 46.39% | 0.0 |
CAT Caterpillar Inc. | 343 | $244,783.98 | $298,780.45 | - | $53,996.47 | 22.06% | -0.623% |
CHRW C.H. Robinson Worldwide, Inc. | 19,656 | $1.7M | $3.04M | - | $1.34M | 78.83% | 0.0 |